Remove 2019 Remove Immunity Remove Labelling
article thumbnail

Paving the way for anti-Abeta active immunotherapy

European Pharmaceutical Review

The vaccination of patients with AN1792 led to the activation of their immune systems, which started producing endogenous anti-Abeta antibodies. Therefore, active immunotherapy to trigger the immune system to produce sustained levels of endogenous antibodies has now become far more attractive.

article thumbnail

BMS scores first approval for psoriasis therapy Sotyktu

pharmaphorum

Bristol-Myers Squibb’s deucravacitinib– one of the main pipeline assets in its $74 billion takeover of Celgene in 2019 – has been approved in its first market as a treatment for moderate-to-severe plaque psoriasis. billion oral psoriasis therapy Otezla (apremilast). Otezla was acquired by Amgen for $13.4

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The Best Probiotics for Hashimoto’s

The Thyroid Pharmacist

This irritation can interrupt the immune system’s ability to regulate itself, and put the body into a perpetual “attack mode” that is counterproductive to healing. Immune system health and gut health are linked. They can help improve digestion and nutrient extraction from the foods we eat, and can also balance the immune system.

article thumbnail

Low Dose Naltrexone and Hashimoto’s

The Thyroid Pharmacist

However, low doses of this medication (hence, low dose naltrexone or LDN), have been found to modulate the immune system and have shown promise in improving cases of autoimmune disease. These include Crohn’s, MS, and Hashimoto’s, as well as other immune system-related conditions such as cancer and HIV/AIDS. Doses of 1.5-4.5

article thumbnail

Pharming preps filing for rare disease drug leniolisib after trial win

pharmaphorum

The Netherlands biotech is developing leniolisib (formerly CDZ173) under license from Novartis for activated PI3K delta syndrome (APDS), an ultra-rare disease with no approved therapies that causes severe immune deficiency and a risk of blood cancers.

article thumbnail

Moving towards oral delivery of biologics

European Pharmaceutical Review

Of the 175 new drugs approved by the US Food and Drug Administration (FDA) between 2016 and 2019, most were biologics. Results from the first open-label, single-centre study of RT-101,6 which was conducted in Australia, were reported at the start of 2020. 2019 [cited 2023Feb]. Oral delivery of biologics via the intestine.

article thumbnail

Targeting tumours with novel radiopharmaceuticals

European Pharmaceutical Review

Granzyme B is an enzyme released by activated immune cells and using this as a in vivo imaging biomarker has great potential to monitor immune cell activation in a variety of inflammatory diseases, autoimmune diseases, cancer and infections.